|
Cephalosporin antibiotic is a kind of semi-synthetic antibiotic containing cephem, which belongs to β-lactam antibiotics and is the derivative of 7-amino cephalosporanic acid, a β-lactam antibiotic. Guo Fanli, researcher of OCN on the pharmaceutical industry, pointed out that, the market share of cephalosporin antibiotics has been significantly improved in China after years of development.
He said that the cephalosporin antibiotics are a class of antibiotics with high efficiency, low toxicity and wide clinical application which has the characteristics of broad spectrum, strong anti-bacterial effect, penicillin - resistant, rare allergy reaction compared with penicillin, etc., It can not only destroy the cell wall of bacteria, but also kill the bacteria during its breeding period without any toxicity to the body.
Guo Fanli pointed out that in 2007, the global anti-infection market size has reached more than 40 billion U.S. dollars, while the cephalosporin antibiotics accounts for a large share, in 2008, there were 65 cephalosporin drugs launched in the worldwide market, so it has become the antibiotic with the fastest growing rate, and it has made tremendous contributions to resist bacterial infection for a long time.
He also pointed out that the research and development of cephalosporin antibiotic began in 1960s in China, and now there have been more than 40 kinds of cephalosporin antibiotics used in the clinical treatment. In the past few years, the domestic growth rate of cephalosporin antibiotics reached about 30%, which has exceeded the average growth rate of pharmaceutical products and as the support on the biotechnology industry from the Government, this growth rate has rising trend.
"2009-2012 China Chemical Pharmaceutical Industry Investment Analysis and Forecast Report" released by OCN said that in 2008, China's cephalosporin antibiotics shared more than 13% of the pharmaceutical market in hospitals, which will continue to grow with the further intensified competition, rapid increase of new products and technologies in the antibiotics market.
|